- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03339115
AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System (AHEAD)
European Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System (AHEAD Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Cardiovalve offers a mitral replacement valve delivered through a transfemoral access and transseptal approach, and is intended to reduce mortality and adverse event rates in selected patients for whom surgical options are not feasible.
Innovation: A truly trans femoral, trans venous delivery of the prosthetic mitral valve which minimizes procedural risk. The Cardiovalve Implant features a dual nitinol frame for robust radial strength with decoupling of the atrial flange and ventricular portion which contains 24 grasping legs designed for atraumatic anchoring of the device to the native mitral annulus. Valve leaflets are made of bovine pericardium. The Cardiovalve implant has a very low left ventricle (LV) protrusion footprint thus reducing the risk of LV outflow tract obstruction and/or interference with the LV. The Cardiovalve delivery system (DS) is designed for transfemoral delivery of the Implant with transseptal access to the left atrium. The catheter assembly is used to center the implant relative to the native mitral valve plane and align it with the left ventricual apex-to-base axis. After valve implantation, the delivery system is withdrawn.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nitza Shoham, VP CA&A
- Phone Number: +972765388142
- Email: nitza@cardiovalve.com
Study Contact Backup
- Name: Lauren Beker, PhD
- Email: lbaker@boston-biomedical.com
Study Locations
-
-
-
Köln, Germany
- Not yet recruiting
- Herzzentrum der Uniklinik Köln
-
Contact:
- Stephan Baldus, MD
- Phone Number: +49 221 478 32511
- Email: stephan.baldus@uk-koeln.de
-
Principal Investigator:
- Stephan Baldus, MD
-
Lübeck, Germany
- Recruiting
- Studienzentrale der Medizinische Klinik II Universitäres Herzzentrum Lübeck
-
Contact:
- Christian Frerker
- Phone Number: 0451 500-44501
- Email: christian.frerker@uksh.de
-
Mainz, Germany
- Not yet recruiting
- Universitaet_Mainz
-
Contact:
- Tobias Ruf, MD
- Email: Tobias.Ruf@unimedizin-mainz.de
-
Contact:
- Stephan von Bardeleben, MD
-
München, Germany
- Recruiting
- Klinikum der Universität München LMU
-
Contact:
- Jörg Hausleiter, MD
- Phone Number: +49 89 4400 72361
- Email: joerg.hausleiter@med.uni-münchen.de
-
Principal Investigator:
- Jörg Hausleiter, MD
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53127
- Recruiting
- Universitätsklinikum Bonn
-
Sub-Investigator:
- Nikos Werner, MD
-
Sub-Investigator:
- Jan-Malte Sinning, MD
-
Sub-Investigator:
- Marcel Weber, MD
-
Contact:
- Georg Nickenig, MD
- Phone Number: +4922828715217
- Email: georg.nickenig@ukbonn.de
-
Principal Investigator:
- Georg Nickenig, MD
-
-
-
-
-
Athens, Greece
- Recruiting
- Hygea
-
Contact:
- Konstantinos Spargias
- Email: kspargias@yahoo.com
-
-
-
-
-
Cotignola, Italy
- Recruiting
- Maria Cecilia Hospital
-
Contact:
- Antonio Colombo, MD
-
Massa, Italy, 54100
- Recruiting
- Fondazione Toscana G. Monasterio-Ospedale del Cuore
-
Contact:
- Sergio Berti, Dr.
-
Milano, Italy, 20129
- Recruiting
- San Raffaele Hospital
-
Contact:
- Paolo Denti, Dr.
- Email: denti.paolo@hsr.it
-
Milano, Italy
- Recruiting
- Policlínico San Donato
-
Contact:
- Francesco Bedogni, MD
- Phone Number: +39 02 5277 4570
- Email: francesco.bedogni@grupposandonato.it
-
Pisa, Italy, 56126
- Recruiting
- A.O.U. Pisana
-
Contact:
- Anna S Petronio, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
General Inclusion Criteria
- Age ≥ 18 years
- NYHA functional II, III or ambulatory IV
- Severe mitral regurgitation (MR grade 3-4+)
- Subject is on optimal guideline-directed medical therapy for heart failure for at least 30 days or CRT if indicated.
- Elevated risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1), frailty and co-morbidities.
- Able to undergo Transesophageal Echocardiography (TEE).
- Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.
The subject commits to return for the scheduled post-operative follow-up visits at the hospital.
Anatomical Inclusion Criteria
- Suitable for femoral access procedure and trans septal catheterization
- Native mitral valve geometry and size and LV outflow tract characteristics compatible with the Cardiovalve (as assessed by the independent Screening Committee)
Cardiovascular Exclusion Criteria
- Prior stroke or TIA within 3 months or Modified Rankin Scale ≥4 disability
- Acute myocardial infarction within the previous 30 days
- Any prior heart valve surgery or transcatheter mitral intervention
- Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
- Rheumatic heart disease or endocarditis within the previous 3 months
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
- Existence of inferior vena cava filter or atrial septal device (contraindicating femoral access and transseptal catheterization)
- Untreated clinically significant coronary artery disease requiring revascularization
- Tricuspid valve disease requiring surgery or severe tricuspid regurgitation
- Aortic or pulmonic valve disease requiring surgery
CRT/ICD implant within 30 days
Anatomical Exclusion Criteria (assessed by pre-procedural imaging)
- Left Ventricular Ejection Fraction (LVEF) <30%
- LV end diastolic diameter > 70mm
- Significant abnormalities of the mitral valve and sub-valvular apparatus.
- Severe mitral annular or leaflets calcification
- Left atrial or LV thrombus or vegetation
- Severe right ventricular dysfunction
Severe tricuspid or aortic valve disease
General Exclusion Criteria
- Subject who is currently participating in an investigational study, other than this study
- Hemodynamic instability defined as systolic pressure < 90mmHg or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart assistance
- Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated, has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications
- Bleeding diathesis or hypercoagulable state
- Active peptic ulcer or active gastrointestinal bleeding
- Pulmonary artery systolic pressure >70 mmHg
- Patients with renal insufficiency (creatinine > 2.5 mg/dL)
- Need for emergent or urgent surgery for any reason or any planned cardiac Surgery within the next 12 months
- Subject with hepatic insufficiency
- Subject has a co-morbid illness that may result in a life expectancy of less than one year
- Active infection that requires antibiotic therapy
- Subject is pregnant, breastfeeding or intend to become pregnant within one year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cardiovalve Transfemoral Mitral Valve
Mitral replacement valve delivered through a transfemoral access and transseptal approach
|
The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary safety endpoint is freedom from all-cause mortality and major adverse events
Time Frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
Freedom from all-cause mortality, all cause hospitalization, major adverse cardiac events (MACE), major device- or procedure- related serious adverse events
|
30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success
Time Frame: Intraoperative, 30 Days
|
Technical success: I. Absence of procedural mortality II. Delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis, LVOT obstruction or paravalvular MR documented by intraoperative imaging [Time Frame:Intraoperative] III. Freedom from emergency surgery or reintervention related to the device or access procedure [Time Frame: 30 days] |
Intraoperative, 30 Days
|
Device Success
Time Frame: Intraoperative
|
I. Absence of procedural mortality or stroke II. Proper placement and positioning of the device III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure |
Intraoperative
|
Device Success
Time Frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
IV. Continued intended safety and performance of the device including:
|
30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
Patient Success
Time Frame: 30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
I. Device success (either optimal or acceptable) II. Patient returned to the pre-procedural setting
|
30 days, 3 Months, 6 Months, 12 Months, and 24 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Nitza Shoham, VP CA&RA, Cardiovalve Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP 17-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Boston Scientific CorporationActive, not recruitingCardiovascular Diseases | Mitral Regurgitation Functional | Mitral Valve DiseaseUnited States, Australia
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Mardil MedicalRecruitingFunctional Mitral RegurgitationCanada, Hungary, France, Germany, Netherlands, Panama, Poland
Clinical Trials on Cardiovalve Transfemoral Mitral Valve
-
Boston Biomedical AssociatesCardiovascular Research Foundation, New York; Cardiovalve Ltd.Active, not recruiting
-
Cardiovalve Ltd.Meditrial Europe Ltd.Recruiting
-
Boston Biomedical AssociatesCardiovascular Research Foundation, New York; Cardiovalve Ltd.Not yet recruitingTricuspid RegurgitationUnited States
-
Pan XiangbinNot yet recruiting
-
Medtronic CardiovascularMedtronicActive, not recruitingMitral Valve InsufficiencyAustralia, United States, Denmark, United Kingdom, France
-
Cardiovalve Ltd.RecruitingTricuspid RegurgitationGermany
-
Southern Illinois UniversityWithdrawnMyocardial Infarction | Mitral RegurgitationUnited States
-
Meshalkin Research Institute of Pathology of CirculationCompletedHypertrophic Obstructive CardiomyopathyRussian Federation
-
Federal University of BahiaCompletedMitral Insufficiency | Mitral StenosisBrazil
-
AUSL Romagna RiminiRecruiting